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PHARMACOVIGILANCE AND 
REPORTING ADVERSE DRUG 
REACTIONS 
Drug therapy is an essential part of health 
care and has become a universally 
accepted form of medical treatment, 
both by health professionals and society 
at large. It is not an exaggeration to say 
that almost every human being has 
had an experience with drug therapy, 
even newborn infants are now exposed 
to immunisations on the day they are 
born. What does society want from drug 
therapy?  Walley (1995) summarised the 
needs of the public as the ‘3 E’, efficacy, 
effectiveness and efficiency.
•	  Efficacy: the drug works (fulfils its 
intended purpose) under optimal 
conditions, and is safe and tolerable
•	  Effectiveness: the drug works under 
the conditions of everyday use
•	  Efficiency: be defined as for every 
dollar spent, the greatest possible 
benefit is gained.
 Pharmacovigilance deals with the 
first 2 Es of drug therapy; efficacy and 
effectiveness.  Any substance capable 
of producing therapeutic effect also 
produces unwanted or adverse effects. 
It is therefore important to identify 
any adverse drug effect to eliminate 
or minimise morbidity and mortality 
due to drug use. ADRs harmfully affect 
patient’s quality of life, increase cost of 
patient care and cause patients to lose 
confidence in their doctors and their 
treatment.
 The year 1961, after the thalidomide 
disaster, that pharmacovigilance really 
took a foothold with huge international 
effort to address the issue of drug 
safety. An Australian obstetrician, 
William McBride reported an increase 
in foetal malformations with unique 
characteristics, later known as 
phocomelia, in the babies of mothers 
prescribed the drug thalidomide 
(Routledge 1998). Dissemination of 
information was relatively slow and by 
the time thalidomide was withdrawn, 
thousands of babies were born with 
phocomelia and other disabling 
congenital malformations. There was 
a huge public outcry and governments 
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worldwide especially within Europe 
and the United States recognised there 
was a need to regulate and monitor 
the safety of drug use. This led to the 
Sixteenth World Health Assembly 
(1963) which adopted a resolution 
for the rapid dissemination of ADRs 
information, and prompted the creation 
of the WHO Pilot Research Project for 
International Drug Monitoring in 1968 
(World Health Organization 2002a). 
This pilot research became the basis for 
pharmacovigilance systems worldwide 
and later resulted in a WHO consultation 
meeting in 1971 which advocated the 
establishment of national centres for 
drug monitoring and provided the first 
guidelines for national centres (World 
Health Organization 2002a).
 According to the World 
Health Organisation (WHO) 
pharmacovigilance is define as the 
science and activities (observational or 
post-approval scientific data gathering 
activities) relating to the detection, 
assessment, understanding and 
prevention of adverse effects or any 
other possible drug-related problems 
with the goals of identifying and 
preventing these problems to the extent 
possible (World Health Organization 
2002a). The most important task 
of pharmacovigilance is to identify 
‘signals’ of drug safety problems as 
early as possible. A signal is defined 
by the WHO as “reported information 
on a possible causal relationship 
between an adverse event and a drug, 
the relationship being unknown or 
incompletely documented previously” 
(World Health Organization 2002b). 
A ‘safety signal’ refers to a concern 
about an excess of adverse events 
compared to what would be expected 
to be associated with a product’s use 
(Food and Drug Administration 2005). 
According to earlier reports, the ultimate 
goal of pharmacovigilance is to foster 
the rational and safe use of medicines, 
the assessment and communication of 
the risks and benefits of drugs on the 
market and educating and informing 
of patients (Uppsala Monitoring Centre 
2000).
 A new medicine must pass three 
hurdles before its approval by the 
national drug regulatory authority. 
Sufficient evidence is required to show 
the new drug to be (World Health 
Organization 2004):
•	  Of good quality
•	  Effective
•	  Safe for the purpose or purposes for 
which it is proposed
 Whereas the first two criteria must be 
met before approval, the issue of safety 
is less certain. Safety is not absolute 
and can only be judged in relation 
to efficacy and limits of acceptable 
safety. Frequently when a new drug is 
marketed, many of its known adverse 
effects including those describe within 
the summary of product characteristics 
(SPC) and in textbooks are adverse 
effects establish during the third phase 
of drug trial (out of 4). This knowledge 
is often incomplete especially in 
regards to frequency, mechanism 
and risk factors. Tests in animals are 
insufficient to predict human safety. 
There is also a possibility that rare yet 
serious adverse events (such as those 
occurring with a frequency of one in 
two thousands) will not be detected in 
94
Med & Health 2014; 9(2): 92-102 Isa N.M. 
the pre-registration development of the 
drug. Prior to drug approval for market, 
it will have to be exposed to a number 
of patients to detect its efficacy and 
toxicity. However, due to the limitation 
of number of patients exposed (ranging 
from as few as 500 to 5000), the 
condition of use differ from ‘real world’ 
clinical practice, the limited duration of 
clinical trials and increasing pressure on 
drug regulators from the pharmaceutical 
industry to shorten the review time for 
new medicines, detection of these less 
frequent adverse events is almost nil 
(Table 1) (Strom 2006). A fatal ADR 
occurring in 1 in 2000 patients treated 
with a new drug will only be recognized 
after 6000 patients have been treated 
and observed, and this is only likely 
provided that the background incidence 
of such a reaction is zero or a causal 
association with the drug is clear (Strom 
2006). Even if detected, the event 
will be incompletely described and 
understood because of too few events. 
In addition, it may also be difficult 
to use clinical trials to ascertain the 
safety profile associated with chronic 
exposure to any product, exposure in 
populations with co-morbid conditions 
or taking multiple medications. More 
information is also frequently needed for 
drug use in specific population groups 
such as children, pregnant women and 
the elderly due to homogenous sample 
populations in clinical trials. Drug-drug 
interactions are also frequently not 
assess with much detail during the drug 
development process. 
 It was the thalidomide disaster (a 
teratogen) which started the era of 
pharmacovigilance; with much irony 
however pharmacovigilance involving 
pregnant women has not developed 
significantly since the disaster occurred. 
Drug trials and research involving 
pregnant women have been almost 
non-existent resulting in a gap in 
knowledge regarding which drugs 
are suitable for use during pregnancy. 
ADRs affect everyone and children 
are not spared. It is reported that 9% 
of children experience ADRs while in 
hospital and that approximately 0.8% 
of children suffers a fatal outcome 
with ADRs. Both figures are likely 
to be an underestimate, as it is well 
recognised that ADRs are significantly 
under reported (Clarkson & Choonara 
2002) Over 50% of medicines used in 
children may not have been studied in 
this age group (MHRA 2013)
DEFINITIONS AND 
CLASSIFICATION OF ADRS
There are various definitions for ADRs 
and ADEs, some of which are widely 
used while others have been proposed. 
The conventional and widely accepted 
definitions are proposed by the Uppsala 
monitoring centre (UMC) and the world 
health organisation (WHO) (Uppsala 
Monitoring Centre 2000; Uppsala 
Monitoring Centre). In defining ADR/E, 
Table 1: Practicality of detecting 
adverse drug reactions in clinical 
trials or post-marketing 
Expected incidence 
of adverse drug 
reactions
Required number of patients 
to detect one event with 95 
percent power
1 in 100 300
1 in 200 600
1 in 1000 3000
1 in 2000 6000
1 in 10000 30000
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various other related terms are defined 
as follows:  
•	  A drug or medicine is a 
pharmaceutical product, used 
in or on the human body for the 
prevention diagnosis or treatment 
of disease, or for the modification 
of physiological function.
•	  An adverse (drug) reaction is 
a response to a medicine which 
is noxious and unintended, and 
which occurs at doses normally 
used in humans for the prophylaxis, 
diagnosis or therapy of disease, or 
for the modification of physiological 
function. (Normal dose clause 
distinguishes adverse reactions 
from poisoning and this clause 
was later refined by Meyboom et 
al. (2000), to caution on patients 
experiencing an adverse reaction 
at normal dose but may indeed be 
a case of high/toxic dose because 
of impaired renal/hepatic excretion 
or other reasons. It is common for 
the term adverse effect to be used 
as synonyms for adverse reaction. 
Adverse effect is seen from the 
point of view of the drug whereas 
an adverse reaction from the point 
of view of the patient (Edwards & 
Aronson 2000). Another commonly 
used definition for an ADR was put 
forward by Edwards and Aronson 
(2000), who define an ADR as “an 
appreciably harmful or unpleasant 
reaction, resulting from an 
intervention related to the use of a 
medicinal product, which predicts 
hazard from future administration 
and warrants prevention or specific 
treatment, or alteration of the 
dosage regimen or withdrawal of 
the product”. The Medicines and 
Healthcare products Regulatory 
Agency (MHRA) in the United 
Kingdom has a broader definition of 
an ADR “as an unwanted or harmful 
reaction experienced following 
the administration of a drug or 
combination of drugs, which is 
suspected to be related to the drug” 
(British Medical Association 2006). 
Unlike the WHO definition, the 
MHRA definition does not exclude 
overdose or drug misuse.  
•	  An unexpected adverse reaction 
is an adverse reaction, the nature or 
severity of which is not consistent 
with domestic labelling or market 
authorisation, or expected from 
characteristics of the drugs.
•	  A side effect is any unintended 
effect of a pharmaceutical product 
occurring at doses normally used 
in man, which is related to the 
pharmacological properties of the 
drug.
•	  A toxic effect is an adverse 
effect of a drug which occurs as 
an exaggeration of the desired 
therapeutic effect and which is not 
common at normal doses (Edwards 
& Aronson 2000). It is always dose-
related. 
•	  An adverse event or experience 
is defined as any untoward medical 
occurrence that may present during 
treatment with a medicine but 
which does not necessarily have 
a causal relationship with the 
treatment.
•	  Serious (not synonymous with 
‘severe’ which is used to describe 
the intensity of a specific outcome) 
adverse events/reactions can be 
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defined as those that:
•	  are life threatening or fatal
•	  cause or prolong hospital 
admission
•	  cause persistent incapacity or 
disability
•	  concern misuse or dependence
•	  Efficacy is the ability of a drug 
to produce the intended effect as 
determined by scientific methods, 
for example in pre-clinical research 
conditions.
RECOGNISING ADRS
Without the ability to recognise ADRs, 
it becomes meaningless to define 
ADRs. Recognising ADRs is not clear-
cut as ADRs may act through the 
same physiological and pathological 
pathways as the disease being treated. 
A patient’s drug history should include 
details regarding illicit drugs, herbal 
and homeopathic medicines, detailing 
any suspected drug-drug interaction 
and cross-reactivity. Concurrent viral 
infections may also increase the risk 
of ADRs; infectious mononucleosis 
increases the risk of rash in patients 
given amoxicillin by a factor of 58 
(Pirmohamed 2005). Genetic factors 
may also be related to an ADR; 
patients with Glucose-6-phosphate 
dehydrogenase (G6PD) deficiency will 
suffer from red cell haemolysis when 
prescribed primaquine.
 The following steps published by the 
WHO are usually recommended to be 
undertaken to identify an ADR (World 
Health Organization 2002b):
•	  Ensure the medicine ordered is 
actually taken by the patient at the 
dose advised
•	  Verify the onset of the suspected 
ADR was after the drug was taken
•	  Determine the time interval 
between beginning of drug 
treatment and onset of adverse 
event
•	  Evaluate the suspected ADR 
after discontinuing the drug(s) or 
reducing the dose. If appropriate, 
restart the drug treatment to monitor 
recurrence of adverse event.
•	  Analyse alternative causes
•	  Use up-to-date literature, national 
pharmacovigilance centre and 
personal/colleague experience to 
verify previous reports/experience 
on the ADR.
CAUSALITY ASSESSMENT
Once an ADR/E is recognised, the 
next step is to determine the cause 
of the ADR/E. Most case reports in 
pharmacovigilance are for ‘suspected’ 
ADR/Es. ADR/Es are rarely specific for a 
drug, and often without a confirmatory 
diagnostic test except for a re-challenge 
which is rarely ethically justified. 
Few ADR/Es are certain. It is often 
quoted “Report it if you are unsure”. 
The WHO as well Malaysia’s national 
pharmacovigilance centre advises to 
report an ADR/E even if you are unsure 
of the cause of the ADR/E or you 
believe it to be unlikely that an ADR/E 
has occurred. When in doubt, report it.
IMPORTANCE AND RELEVANCE 
OF IDENTIFYING AND 
DETECTING ADRS/ADES
ADRs affect a significant number 
of patients. A two year prospective 
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study in the UK involving 19 general 
practitioners and 872 patients by Martys 
(1979) reported that up to 41% of patients 
had some type of adverse drug effect 
with 90% of the adverse effect occurring 
by the fourth day of prescription (Martys 
1979). A prospective cross sectional 
study of a representative nationwide 
(33 hospitals) sample of medical wards 
by Pouyanne et al. (1998) reported that 
3.19% (100 out of 3137) of patients 
were admitted to hospital because of 
an adverse drug reaction. The patients 
tended to be older and were more likely 
to be female. Four (0.12%) patients died 
as a direct result of the adverse effect. 
The authors however do caution that 
a larger proportion of adverse effects 
probably occur in the community but 
do not give rise to hospital admission. 
A meta-analysis commonly cited as 
a reference is by Lazarou et al. (1998) 
which analysed 39 pharmacovigilance 
studies. The meta-analysis reported the 
incidence of serious ADRs to be 2.1%, 
incidence of fatal ADRs to be 0.19% and 
overall incidence of ADRs to be 10.9% 
for in hospital patients. The incidence 
for patients admitted to hospital due 
to serious ADRs is 4.7% and with 
fatal ADRs is 0.13%. The overall ADR 
incidence was reported to be 15.1% of 
hospital patients. Lazarou et al. (1998) 
then estimated 106 000 deaths were 
caused by ADRs in the United States 
(1994) which would indicate fatal ADRs 
to be the fourth to sixth leading cause 
of death.
 A meta-analysis of 68 studies 
involving a total of 123 794 patients by 
Beijer and Blaey (2002) reported that 
4.9% (CI 0.1%) of hospital admissions 
are related to ADRs. Twelve  studies 
provided data on unnecessary hospital 
admissions, of which 407 out of 1410 
(28.9%) were regarded as preventable. 
Beijer and Blaey (2002) also reported 
that in people aged over 65 years, 
the admission rate due to a suspected 
ADR was higher (16%) compared to 
the younger individuals (4%). A cost 
estimate for Netherlands was reported 
in which the authors estimated that 
preventable ADR related admissions 
cost the Netherland health care system 
was  £110 to £256 million, annually ( 
Beijer & Blaey 2002). A summary of 
13 studies by Goettler  et al. (1997) 
reported that ADRs are responsible for 
a mean length of stay in hospital of 9.6 
days with a median of 8.7 days. They 
also noted that annual direct cost of 
hospital admissions due to ADRs (1997) 
for Germany was approximately 1050 
Million DM (525 million Euro) and more 
importantly 30.7% of admissions due 
to ADRs were preventable, providing 
a potential savings of 350 million DM 
(175 million Euro) (Goettler et al. 1997). 
 A two year observational study by 
Buajordet et al. (2001) examined the 
cause of death for 732 patients out of 
a total of 13 992 admissions. Buajordet 
reported 18.2% (133 out of 732) of 
deaths were classified as fatal adverse 
drug events (FADE) with 64 (48%) of 
the deaths caused directly by one or 
more drugs. Half of the cases (66/133) 
were judged to be related to various 
degrees of inappropriate administration 
or use of drug(s), therefore potentially 
avoidable (Pirmohamed et al. 2004).
 More recent data were provided 
by Pirmohamed et al. (2004) with his 
prospective study involving 18 820 
patients admitted to two hospitals in 
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Merseyside over a six month period. 
Pirmohamed et al. (2004) reported 
that ADRs caused 1225 admissions 
(6.5%, 95% CI of 6.2% to 6.9%) with 
95% classified as type A ADRs. More 
importantly, Pirmohamed et al. (2004) 
reported 72% of the ADRs were 
avoidable. The proportion of women 
admitted was significantly higher in the 
ADR group (59% vs 52%) compared to 
the non-ADR group. 2.3% of patients 
died as a direct result of the index 
ADR (0.15% of all patients admitted) 
suggesting that ADRs are responsible 
for the death of approximately 5700 
patients annually. Patients admitted 
with an ADR had a median stay of eight 
days resulting in the projected annual 
cost of ADR related admissions to the 
NHS of £466 million. This cost estimate 
does not include ADRs suffered by 
patients while being hospitalised and 
ADRs in primary care that did not 
result in hospital admissions. A pilot 
study in 2006 by Davies et al. (2006) 
assessed ADRs which occurred during 
hospitalisation rather than the cause of 
admission. They reported that 19.2% 
(24 out of 125 patients) of patients 
suffered one or more ADRs while 
hospitalised with a median length of 
stay which was significantly longer than 
patients admitted for other reasons (14.5 
days vs. 8 days) (Davies et al. 2006). 
With the rising cost of health care (bed 
occupancy cost and treatment cost), it 
would be safe to assume that the current 
cost of ADRs to the health services in 
the UK should have exceeded £500 
million pounds, possibly approaching 
£2 billion in 2014.  
 ADRs affect all patient populations, 
although information regarding special 
populations such as children and 
pregnant women are limited. In a 10 year 
retrospective study by Le et al. (2006) at 
the Miller Children’s Hospital, US, the 
overall incidence of ADRs per hospital 
admission was 1.6% with an annual 
incidence of 0.4 -2.3%. However, this 
study omitted patients with medication 
errors and patients suffering ADRs 
out of hospital. Impicciatore et al. 
(2001) conducted a systematic review 
and meta-analysis to determine the 
incidence of ADRs in the paediatric 
population. The review included 17 
studies. Impicciatore reported a higher 
overall incidence of ADRs among 
hospitalised children of 9.53% (95% 
CI: 6.81 to 12.26) when compared with 
Le et al. (2006) with severe reactions 
accounting for 12.29% of the total. The 
overall rate of paediatric admissions 
due to ADRs was 2.09% (95% CI:  1.02 
to 3.77) with 39.3% of the ADRs being 
severe reactions. The overall incidence 
of ADRs was 1.46% (95% CI: 0.70 to 
3.03) for outpatient children.
PHARMACOVIGILANCE IN 
MALAYSIA
It is clear by now that little information 
has been quoted from Malaysia. 
Information from Malaysia is scanty 
and pharmacovigilance researches 
are frequently underpowered 
to be referenced. Funding for 
pharmacovigilance type research is 
almost non-existent, although clearly 
lacking and urgently needed. It should 
be noted that Malaysia has been a 
member of the WHO Programme for 
International Drug Monitoring since 
the year 1990. However, Malaysia’s 
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contribution towards the programme 
could be classified as moderate at 
best. Although there are currently 
118 member countries contributing 
to the programme, it is widely 
acknowledged that most contributions 
to the programme originate from a few 
countries, mainly the United States, 
Europe and Japan.
 Pharmacovigilance in Malaysia 
is under the responsibility of the 
Malaysian Adverse Drug Reactions 
Advisory Committee (MADRAC) which 
was established under Drug Control 
Authority (DCA). MADRAC provides 
DCA with important information 
pertaining to local and international 
drug safety issues, as well as advises 
DCA on risk management and risk 
communication following effective 
assessment of the benefit-risk profile of 
drugs. The National Centre for Adverse 
Drug Reaction Monitoring acts as the 
secretariat to MADRAC (MADRAC 
2012). The main form of ADR reporting 
system in Malaysia is a spontaneous 
reporting system, frequently known 
as the ‘blue card’ system as the card 
used to report ADR is blue in colour. 
As the name suggests, this form of 
reporting system is voluntary and is 
frequently plague by low reporting 
rates. A systematic review by Hazell 
and Shakir (2006) reported the median 
under-reporting rate from 37 studies 
across 12 countries was 94% with an 
under-reporting rate of 80% for more 
serious ADRs. In the UK, the number 
of ADR reports has remained stable at 
25 000 per year for the past 10 years 
(MHRA 2014). In Malaysia, the number 
of reports has average at less than 6000 
for the past 10 years (Bulletin MADRAC 
2014). Reporting of ADR to MADRAC 
has seen an increase for the past 5 
years, doubling from 5850 reports in 
2009 to 11473 reports in 2013. This 
increase is partly due to reinforcement 
of ADR reporting for immunization, 
which contributes approximately a fifth 
of all ADR reports (Bulletin MADRAC 
2014). However, further analysis reveals 
a less positive scenario. Pharmacist 
contributes the majority of reports 
(54.7%), followed by ministry of health 
doctors (13.6%) and product registration 
holders (10.8%). General practitioners 
(GPs) and private specialists contributed 
a meagre 1% of reports. These figures 
are for the year 2013 (BM 2014) 
although the trend does not deviate 
far from this in previous years. Unlike 
the UK, reports from GPs form the 
backbone of ADR reporting with total 
reporting from doctors contributing to 
almost 50% (MHRA 2014).  As doctors, 
certain important information that 
would help in causality assessment as 
well as severity assessment is readily 
available when compared to other 
health professionals. MADRAC has 
now shifted its focus on quality reports 
instead of quantity. The WHO Uppsala 
Monitoring Centre measures individual 
case safety report quality using a score 
system between 0 (poorly documented 
case) to 1 (well documented). Over the 
past five years, reports from Malaysia 
have consistently obtained an average 
completeness score of around 0.45 
(Bulletin MADRAC 2014). It is however 
not prudent to advise that only doctors 
should report an ADR, however the 
importance and the advantages of 
doctors reporting ADR encountered 
must be stressed repeatedly. 
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 Spontaneous reporting is the 
principal pharmacovigilance system 
in use worldwide with proven 
effectiveness and a good track record 
resulting in the avoidance of many 
potential disasters and the identification 
of new or previously unknown drug 
related adverse effects. Its main 
advantages include wide population 
coverage, relatively low cost and 
resource utilisation (given the huge 
number of population covered and the 
continuous monitoring of all drugs), 
and a well established methodology 
(British Medical Association 2006; 
Meyboom et al. 1999) However, 
spontaneous reporting systems depend 
on voluntary reporting of health care 
professionals, hence the reporting rate 
or under-reporting rate becomes the 
limiting factor determining the success 
and usefulness of such an approach to 
pharmacovigilance. In Malaysia, low 
reporting rates causes signals to be not 
generated and even if generated, are 
often late. We instead rely on warnings 
and precautionary statements from the 
US and Europe, which is a weakness 
that needs to be looked into further 
and not ignored. Drugs marketed 
in Malaysia, our population, our 
environment and most importantly our 
prescribers are inherently different from 
the US and Europe. Relying on signals 
from countries with many differences 
is a weakness which unfortunately is 
difficult to overcome. The warnings may 
not affect Malaysia as the drug may not 
even be marketed here or as an Asian 
population, we may respond differently. 
Much more worrying however is the 
opposite. ADR/Es occurring commonly 
here but is not detected because no 
signals is being generated from the US 
or Europe. 
CONCLUSION
There is a common misconception 
especially among the public that all 
drugs approved by the authorities 
have all their side-effects or possible 
adverse reactions known and that the 
role of the authorities is to monitor any 
drug on the market for unexpected 
adverse reactions and to withdraw 
drugs from the market. In fact, the 
number of drug withdrawals on the 
grounds of quality, efficacy, and safety 
has remained relatively stable since 
the 70s with only 24 withdrawals out 
of 583 new active substances (new 
chemical, biological or pharmaceutical 
substances for human consumption) 
approved between 1972 and 1994 with 
a 10 year survival of all new active 
substances at approximately 88%, 
a low attrition rate when compared 
with other consumer products (Jeffrey 
et al. 1998). This brings forward an 
important task for pharmacovigilance, 
the dissemination of information and 
educating society regarding drug safety 
and pharmacovigilance. The message 
that an approved drug does not mean 
100% safety and the identification 
of unknown adverse reactions after 
marketing approval is necessary must 
be presented with tact to avoid mass 
panic and greater misunderstanding. 
The recognition of adverse reactions, 
including serious adverse reactions does 
not automatically justify the withdrawal 
of a drug from the market. A balanced 
assessment between benefit and harm 
must be made and this assessment 
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should be presented to the public and 
more importantly to health practitioners, 
to reduce harm and maximise the 
benefits. This will however remain a 
challenge in the foreseeable future 
for pharmacovigilance and national 
health authorities in particular, because 
at the core of this objective coming 
to realization is improving ADR/E 
reporting rates. 
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